Date: 2016-06-21
Type of information: Distribution agreement
Compound: Dynabeads™ CD3/CD28 Cell Therapy System
Company: Adaptimmune Therapeutics (UK) Thermo Fisher Scientific (USA - MA)
Therapeutic area: Technology - Services
Type agreement: development distribution
Action mechanism:
Disease:
Details: * On June 21, 2016, Adaptimmune Therapeutics announced that it has entered into a commercial development and supply agreement with Thermo Fisher Scientific. The new 10-year agreement augments Adaptimmune’s exclusive license and supply relationship with Thermo Fisher for the Dynabeads CD3/CD28 Cell Therapy System (CTS™)* for use in the manufacture of Adaptimmune’s SPEAR™ T-cell therapies. Dynabeads™ CD3/CD28 CTS is designed to isolate, activate and expand human T-cells. This technology provides coordinated and simultaneous activation and co-stimulation signals to T-cells, a process that is reported to produce T-cells with enhanced proliferation and with characteristics that enable prolonged persistence in vivo. Adaptimmune has an exclusive license for the IP associated with the use of Dynabeads CD3/CD28 to expand and activate all T cell receptors (TCRs)-transduced T-cells in cancer, infectious and autoimmune diseases. The manufacturing process consists of isolating T-cells from the blood of cancer patients; transferring affinity enhanced TCRs, which have been modified to recognize cancer cells, into the cells; activating and expanding the T-cells using Dynabeads CD3/CD28; and, introducing the affinity enhanced cells back into the patient to enable the patient's immune system to respond and attack cancer.
Financial terms:
Latest news:
